C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 123 filers reported holding C4 THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $428,236 | +225.6% | 75,794 | +7.2% | 0.08% | +192.9% |
| Q3 2023 | $131,508 | -18.5% | 70,703 | +20.6% | 0.03% | -12.5% |
| Q2 2023 | $161,279 | -3.6% | 58,647 | +10.1% | 0.03% | -33.3% |
| Q1 2023 | $167,293 | +13.7% | 53,278 | +113.7% | 0.05% | -66.4% |
| Q4 2022 | $147,105 | -34.0% | 24,933 | -2.1% | 0.14% | -30.2% |
| Q3 2022 | $223,000 | +21.9% | 25,470 | +4.8% | 0.20% | +47.5% |
| Q2 2022 | $183,000 | -65.5% | 24,314 | +11.2% | 0.14% | -44.4% |
| Q1 2022 | $531,000 | -40.7% | 21,868 | -21.3% | 0.25% | -23.3% |
| Q4 2021 | $895,000 | – | 27,791 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |